MRR in the Pharma Industry.
Abstract
The added value of MRR in the pharmaceutical industry is validated. Targets are confidential and cannot be added in the abstract. Nu further details can be given Nu further details can be given Nu further details can be givenResearcher(s)
- Promoter: Herrebout Wouter
- Fellow: Bogaerts Jonathan
Research team(s)
Project type(s)
- Research Project
Studying the structure-activity relationship in artemisinin-transferrin adducts by means of Raman optical activity.
Abstract
Cancer has become an ever increasing risk in our aging Western world. As a consequence of a rise in diagnosed cancer cases, in combination with the limitations and side effects caused by conventional cancer treatments, new cancer therapies with high efficiency and limited side effects are much sought after. Artemisinin, a drug already used in malaria treatment, is showing great potential as a candidate for such next generation cancer treatment. Unfortunately, due to the complexity of the current drug assembly, as artemisinin is delivered to the cancer cells bound to the iron transporting protein transferrin, efforts in clinical development of the drug is slow. In this project, a protocol for the detailed structural analysis of artemisinin-transferrin complexes is proposed. By studying the solution phase structure of the drug, using state-of-the-art chiroptical spectroscopic techniques combined with cutting-edge computational chemistry, and correlating these findings with anticancer activity studies, it is hoped that the process of developing artemisinin into a viable anticancer drug will be stream lined before the costly (both with respect to money and time) clinical trials. Therefore, it is also envisioned that the protocol will define precedence for other pre-clinical protein drug studies.Researcher(s)
- Promoter: Johannessen Christian
- Fellow: Bogaerts Jonathan
Research team(s)
Project type(s)
- Research Project
Studying the structure-activity relationship in artemisinin-transferrin adducts by means of Raman optical activity
Abstract
Cancer has become an ever increasing risk in our aging Western world. As a consequence of a rise in diagnosed cancer cases, in combination with the limitations and side effects caused by conventional cancer treatments, new cancer therapies with high efficiency and limited side effects are much sought after. Artemisinin, a drug already used in malaria treatment, is showing great potential as a candidate for such next generation cancer treatment. Unfortunately, due to the complexity of the current drug assembly, as artemisinin is delivered to the cancer cells bound to the iron transporting protein transferrin, efforts in clinical development of the drug is slow. In this project, a protocol for the detailed structural analysis of artemisinin-transferrin complexes is proposed. By studying the solution phase structure of the drug, using state-of-the-art chiroptical spectroscopic techniques combined with cutting-edge computational chemistry, and correlating these findings with anticancer activity studies, it is hoped that the process of developing artemisinin into a viable anticancer drug will be stream lined before the costly (both with respect to money and time) clinical trials. Therefore, it is also envisioned that the protocol will define precedence for other pre-clinical protein drug studies.Researcher(s)
- Promoter: Johannessen Christian
- Fellow: Bogaerts Jonathan
Research team(s)
Project type(s)
- Research Project
Studying structure-function relationships in transferrin-artemisinin adducts by means of Raman optical activity.
Abstract
Cancer has become an ever increasing risk in our aging Western world. As a consequence of a rise in diagnosed cancer cases, in combination with the limitations and side effects caused by conventional cancer treatments, new canter therapies with high efficiency and limited side effects are much sought after. Artemisinin, a drug already used in malaria treatment, is showing great potential as a candidate for such next generation cancer treatment. Unfortunately, due to the complexity of the current drug assembly, as artemisinin is delivered to the cancer cells bound to the iron transporting protein transferrin, efforts in clinical development of the drug is slow. In this project, a protocol for the detailed structural analysis of artemisinin-transferrin complexes is proposed. By studying the solution phase structure of the drug, using state-of-the-art chiroptical spectroscopic techniques combined with cutting-edge computational chemistry, and correlating these findings with activity studies, it is hoped that the process of developing artemisinin into a viable anti-cancer drug will be stream lined before the costly (both with respect to money and time) clinical trials. Therefore, it is also envisioned that the protocol will define precedence for other pre-clinical drug studies.Researcher(s)
- Promoter: Johannessen Christian
- Fellow: Bogaerts Jonathan
Research team(s)
Project type(s)
- Research Project